"A comment by U.S. Senator Sam Brownback (R-KS) in Health Affairs highlights research by David Ridley, Henry Grabowski, and Jeffrey Moe. Current federal legislation (the Food and Drug Administration Revitalization Act of 2007) incorporates the Duke professors' proposal that the FDA create 'priority voucher reviews' for pharmaceutical companies that introduce drugs fo neglected or tropical diseases, as an alternative to extended patent life."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment